Business
Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update
With increasing demand for needed treatments designed for women, Daré is taking action to make its proprietary Sildenafil Cream formulation available via prescription this yearEnables women to access a solution that they want and needCreates an opportunity to accelerate revenue generation from this proprietary formulation Daré expects to start recording revenue and cash flow in the 4th quarter of this year Conference call today at 4:30 p.m. ET to discuss the expanded business strategy to integra
About this update from Dare Bioscience, Inc.
[{"type":"image","alt":"Daré Bioscience, Inc.","displaySize":"","headline":null,"caption":"Daré Bioscience, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":226,"url":"https://media.zenfs.com/en/globenewswire.com/e6d6ede7b4fb465dc2ad08194cf35dbd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ch5vpzW1QsXLUt._W_BLpg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMxNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e6d6ede7b4fb465dc2ad08194cf35dbd","width":300,"height":226}},"lazy":false},{"type":"text","content":"With increasing demand for needed treatments designed for women, Daré is taking action to make its proprietary Sildenafil Cream formulation available via prescription this year","length":176,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Enables women to access a solution that they want and need","length":58,"tagName":"p"}]},{"val":[{"type":"text","content":"Creates an opportunity to accelerate revenue generation from this proprietary formulation ","length":89,"tagName":"p"}]},{"val":[{"type":"text","content":"Daré expects to start recording revenue and cash flow in the 4th quarter of this year","length":90,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":237,"olType":false},{"type":"text","content":"Conference call today at 4:30 p.m. ET to discuss the expanded business strategy to integrate 503B compounding as part of a dual-path approach to bring select Daré proprietary formulations to market as soon as practicable","length":220,"tagName":"p"},{"type":"text","content":"SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today reported financial results for the year ended December 31, 2024 and provided a company update.","length":310,"tagName":"p"},{"type":"text","content":"“Daré exists to accelerate innovation in women’s health and our goal is to fulfill the urgent need for access to evidence-based treatment options. We are proud to announce that we are taking action to make our proprietary Sildenafil Cream formulation available via prescription this year as a compounded drug under Section 503B of the FDCA, because we believe women should not have to wait for access to our formulation when an alterna...